The global community has committed to ending the TB epidemic by 2030. That’s a lofty goal – but an achievable one. Momentum has never been greater among all parts of the TB community.
But what does the “day-to-day” of ending TB really involve? The World Health Organization’s End TB Strategy defines specific priorities to keep all stakeholders on track. For FIND, together with our colleagues and partners working in diagnostics, one of those priorities is to ensure “early diagnosis of TB including universal drug susceptibility testing, and systematic screening of contacts and high-risk groups.” To achieve this, effective TB laboratory services are critical.
National TB reference laboratories (NTRLs) are the cornerstone of a country’s TB laboratory network. Accreditation of NTRLs is key to strengthening a country’s diagnostic network, so that quality-assured diagnostic services can be made available to the people who need them.
Ethiopia and Kenya have been identified by WHO as high-burden countries for TB, multidrug-resistant TB, and TB/HIV – and are therefore global priorities for TB laboratory strengthening. BD Global Health and FIND have teamed up to support NTRL accreditation and expanding country capacity for universal drug susceptibility testing in these two countries.
For more information on this project, please contact Zachary Katz, Chief Access Officer, email@example.com
|According to the 2017 WHO Global Tuberculosis Report, in 2016: